Preliminary results emerged from some clinical studies testify that the bivalent mRNA vaccines containing sequences of BA.4/5 sublineages and approved for clinical use in Italy display neutralizing capacity of omicron variants (including the more recent and insidious sublineages BA.2.75.2, BQ.1.1 and XXB.1.1) higher than that of the original monovalent formulations. Thus, mRNA-based bivalent vaccines appear to present a substantial advantage over previous monovalent vaccines, making their use preferable for immunizing subjects at higher risk of SARS-CoV-2 infection (e.g., the healthcare personnel) or developing more aggressive forms of disease (elderly, frail and/or immunocompromised subjects), exhibiting also a safety profile comparable to that of the previous monovalent vaccines.
Vaccini bivalenti contro COVID-19
Lippi, Giuseppe
;Mattiuzzi, Camilla
2022-01-01
Abstract
Preliminary results emerged from some clinical studies testify that the bivalent mRNA vaccines containing sequences of BA.4/5 sublineages and approved for clinical use in Italy display neutralizing capacity of omicron variants (including the more recent and insidious sublineages BA.2.75.2, BQ.1.1 and XXB.1.1) higher than that of the original monovalent formulations. Thus, mRNA-based bivalent vaccines appear to present a substantial advantage over previous monovalent vaccines, making their use preferable for immunizing subjects at higher risk of SARS-CoV-2 infection (e.g., the healthcare personnel) or developing more aggressive forms of disease (elderly, frail and/or immunocompromised subjects), exhibiting also a safety profile comparable to that of the previous monovalent vaccines.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
